Bafnapharm Balance Sheet Annual

Trade

BSE: 532989 | NSE: BAFNAPH | ISIN: INE878I01022 | Sector: Biotechnology & Drugs

81.74 +1.74 (2.18%)Updated : 25 Nov 2024

Interim Data

Annual Data

Fiscal Period	2024	2023	2022	2021
Period End Date	Mar 24	Mar 23	Mar 22	Mar 21
Cash Equivalents	1.40	7.81	0.17	1.80
Short Term Investments	0.70	-	-	-
Cashand Short Term Investments	2.10	7.81	0.17	1.80
Accounts Receivable- Trade Net	45.39	41.15	14.78	9.56
Total Receivables Net	46.12	41.68	15.50	9.56
Total Inventory	29.64	22.22	20.28	15.44
Other Current Assets Total	16.61	15.23	14.92	22.86
Total Current Assets	94.47	87.31	50.88	49.67
Property/ Plant/ Equipment Total- Net	50.71	40.23	38.85	36.80
Intangibles Net	1.77	1.50	0.00	-
Long Term Investments	0.73	-	0.42	-
Total Assets	147.68	129.58	90.14	86.47
Accounts Payable	35.42	28.46	12.40	10.69
Notes Payable/ Short Term Debt	13.64	14.49	5.74	10.00
Other Currentliabilities Total	5.02	3.41	3.87	3.12
Total Current Liabilities	54.08	46.48	22.01	24.31
Long Term Debt	10.75	8.43	5.32	5.29
Total Long Term Debt	10.75	8.43	5.32	5.29
Total Debt	24.39	22.92	11.06	15.79
Other Liabilities Total	2.01	1.22	0.85	0.10
Total Liabilities	66.84	56.13	28.18	29.69
Common Stock Total	23.66	23.66	23.66	23.66
Retained Earnings( Accumulated Deficit)	57.18	-25.58	38.31	33.11
Total Equity	80.84	73.45	61.96	56.77
Total Liabilities Shareholders' Equity	147.68	129.58	90.14	86.47
Total Common Shares Outstanding	2.37	2.37	2.37	2.37
Tangible Book Valueper Share Common Eq	33.42	30.42	26.19	24.00
Prepaid Expenses	-	0.37	-	-
Property/ Plant/ Equipment Total- Gross	-	92.43	-	-
Accumulated Depreciation Total	-	-52.36	-	-
Other Long Term Assets Total	-	0.54	-	-
Accrued Expenses	-	0.11	-	-
Additional Paid- In Capital	-	75.38	-	-
Current Portof LT Debt/ Capital Leases	-	-	-	0.50